Neowise Biotechnology
Suzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $300M
Overview
Neowise develops TCR-T cell therapies for solid tumors using its proprietary CAST® platform for natural TCR discovery.
OncologyImmunology
Technology Platform
CAST® platform for high-throughput discovery of natural TCRs targeting tumor antigens, integrating computational analysis with experimental validation to screen for high-affinity antigen-specific TCRs.
Opportunities
Large addressable market in solid tumors where current cell therapies are limited, potential for platform licensing deals, and expansion into additional tumor antigens beyond PRAME and KRAS.
Risk Factors
Clinical trial failures common in cell therapy, competitive landscape with established TCR-T companies, regulatory challenges for novel therapies, and dependence on continued funding.
Competitive Landscape
Competes with Adaptimmune, Immunocore, and T-Cure Bio in TCR-T space; differentiates through natural TCR discovery platform and focus on solid tumors with high-throughput screening capabilities.